"Biomateriales y Nanoestructuras" 
- Viernes 22 de febrero de 2012 - 16.00 horas
Salón de actos de Bionand
Parque tecnológico de Andalucía
Severo Ochoa, s/n. 29590 Campanillas. Málaga
Dra. María Vallet Regí
Investigadora Principal en el Centro de Investigación Biomédica en Red de Bioingeniaría, Biomateriales y Nanomedicina (CIBER-BBN).
Catedrática en Química Inorgánica. Universidad Complutense de Madrid.
* Selected references:
1.-M Vallet-Regí and E. Ruiz-Hernández. BIOCERAMICS: FROM BONE REGENERATION TO CANCER NANOMEDICINE. Adv. Mater. 23, 5177–5218. (2011).
2.-M. Vallet-Regí, M. Colilla and B. González. MEDICAL APPLICATIONS OF ORGANIC-INORGANIC HYBRID MATERIALS WITHIN THE FIELD OF SILICA-BASED BIOCERAMICS. Chem. Soc. Rev. 70, 596-607 (2011).
3.-E. Ruiz-Hernández, A. Baeza, M. Vallet-Regí. SMART DRUG DELIVERY THROUGH DNA/MAGNETIC NANOPARTICLE GATES. ACS Nano. 5 (2), 1259–1266 (2011).
4.-M. Vallet-Regí, E. Ruiz-Hernández, B. González, A. Baeza. DESIGN OF SMART NANOMATERIALS FOR DRUG AND GENE DELIVERY. J. Biomater. Tissue. Eng. 1, 6-29 (2011).
5.-J. Simchenn, A. Baeza, D. Ruiz, M. Esplandiu, M. Vallet-Regí. ASYMMETRIC HYBRID SILICA NANOMOTORS FOR CAPTURE AND CARGO TRANSPORT: TOWARDS A NOVEL MOTION-BASED DNA SENSOR. Small. 8(13), 2053-2059 (2012).
6.-M. Vallet-Regí, International Scholarly Research Network ISRN Materials Science, Volume 2012, Article ID 608548, 20 pages, doi:10.5402/2012/608548
7.-A. Baeza, E. Guisasola, E. Ruiz-Hernández and M. Vallet-Regí. MAGNETICALLY TRIGGERED MULTI-DRUG RELEASE BY HYBRID MESOPOROUS SILICA NANOPARTICLES. Chem. Mater. 24, 517-524 (2012).
8.-Daniel Arcos, María Vallet-Regí, BIOCERAMICS FOR DRUG DELIVERY, Acta Materialia 61 (2013) 890–911
2.-M. Vallet-Regí, M. Colilla and B. González. MEDICAL APPLICATIONS OF ORGANIC-INORGANIC HYBRID MATERIALS WITHIN THE FIELD OF SILICA-BASED BIOCERAMICS. Chem. Soc. Rev. 70, 596-607 (2011).
3.-E. Ruiz-Hernández, A. Baeza, M. Vallet-Regí. SMART DRUG DELIVERY THROUGH DNA/MAGNETIC NANOPARTICLE GATES. ACS Nano. 5 (2), 1259–1266 (2011).
4.-M. Vallet-Regí, E. Ruiz-Hernández, B. González, A. Baeza. DESIGN OF SMART NANOMATERIALS FOR DRUG AND GENE DELIVERY. J. Biomater. Tissue. Eng. 1, 6-29 (2011).
5.-J. Simchenn, A. Baeza, D. Ruiz, M. Esplandiu, M. Vallet-Regí. ASYMMETRIC HYBRID SILICA NANOMOTORS FOR CAPTURE AND CARGO TRANSPORT: TOWARDS A NOVEL MOTION-BASED DNA SENSOR. Small. 8(13), 2053-2059 (2012).
6.-M. Vallet-Regí, International Scholarly Research Network ISRN Materials Science, Volume 2012, Article ID 608548, 20 pages, doi:10.5402/2012/608548
7.-A. Baeza, E. Guisasola, E. Ruiz-Hernández and M. Vallet-Regí. MAGNETICALLY TRIGGERED MULTI-DRUG RELEASE BY HYBRID MESOPOROUS SILICA NANOPARTICLES. Chem. Mater. 24, 517-524 (2012).
8.-Daniel Arcos, María Vallet-Regí, BIOCERAMICS FOR DRUG DELIVERY, Acta Materialia 61 (2013) 890–911
"Marcadores genéticos en Espondilitis anquilosante. Implicaciones patogénicas y clínicas"
- Viernes 14 de diciembre de 2012 - 13.00 horas
Hospital Universitario Reina Sofía. Córdoba
Edificio Consultas Externas, nivel -1. Aula 6
Dr. Juan Mulero Mendoza
Jefe del Servicio de Reumatología del H.U.Puerta de Hierro de Madrid. Profesor de la Universidad Autónoma de Madrid y Coordinador del Área de Genética Clínica del Grupo Español para el Estudio de las Espondiloartropatías de la Sociedad Española de Reumatología (GRESSER).
* Selected references:
1.-Schiotis R, Bartolomé N, Sánchez A, Szczypiorska M, Sanz J, Cuende E, Collantes Estevez E, Martínez A, Tejedor D, Artieda M, Buzoianu A, Mulero J. Both baseline clinical factors and genetic polymorphisms influence the development of severe functional status in ankylosing spondylitis. PLoS One. 2012;7(9):e43428.
2.-Bartolomé N, Szczypiorska M, Sánchez A, Sanz J, Juanola-Roura X, Gratacós J, Zarco-Montejo P, Collantes E, Martínez A, Tejedor D, Artieda M, Mulero J. Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. Rheumatology (Oxford). 2012 Aug;51(8):1471-8
3.-Díaz-Peña R, Aransay AM, Suárez-Álvarez B, Bruges-Armas J, Rodríguez-Ezpeleta N, Regueiro M, Pimentel-Santos FM, Mulero J, Sánchez A, Collantes E,Queiro R, Ballina J, Alves H, López-Larrea C. A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. Ann Rheum Dis. 2012 May;71(5):714-7
4.-Szczypiorska M, Sánchez A, Bartolomé N, Arteta D, Sanz J, Brito E, Fernández P, Collantes E, Martínez A, Tejedor D, Artieda M, Mulero J. ERAP1 polymorphisms and haplotypes are associated with ankylosing spondylitis susceptibility and functional severity in a Spanish population. Rheumatology (Oxford). 2011 Nov;50(11):1969-75
5.-Díaz-Peña R, Aransay AM, Bruges-Armas J, López-Vázquez A, Rodríguez-Ezpeleta N, Mendibil I, Sánchez A, Torre-Alonso JC, Bettencourt BF, Mulero J,Collantes E, López-Larrea C. Fine mapping of a major histocompatibility complex in ankylosing spondylitis: association of the HLA-DPA1 and HLA-DPB1 regions. Arthritis Rheum. 2011 Nov;63(11):3305-12.
6.-Association of the intergenic single-nucleotide polymorphism rs10865331 (2p15) with ankylosing spondylitis in a Spanish population. Sánchez A, Szczypiorska M, Juanola X, Bartolomé N, Gratacós J, Zarco P, Collantes E, Artieda M, Martínez A, Tejedor D, Mulero J. J Rheumatol. 2010 Nov;37(11):2345-7.
2.-Bartolomé N, Szczypiorska M, Sánchez A, Sanz J, Juanola-Roura X, Gratacós J, Zarco-Montejo P, Collantes E, Martínez A, Tejedor D, Artieda M, Mulero J. Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. Rheumatology (Oxford). 2012 Aug;51(8):1471-8
3.-Díaz-Peña R, Aransay AM, Suárez-Álvarez B, Bruges-Armas J, Rodríguez-Ezpeleta N, Regueiro M, Pimentel-Santos FM, Mulero J, Sánchez A, Collantes E,Queiro R, Ballina J, Alves H, López-Larrea C. A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. Ann Rheum Dis. 2012 May;71(5):714-7
4.-Szczypiorska M, Sánchez A, Bartolomé N, Arteta D, Sanz J, Brito E, Fernández P, Collantes E, Martínez A, Tejedor D, Artieda M, Mulero J. ERAP1 polymorphisms and haplotypes are associated with ankylosing spondylitis susceptibility and functional severity in a Spanish population. Rheumatology (Oxford). 2011 Nov;50(11):1969-75
5.-Díaz-Peña R, Aransay AM, Bruges-Armas J, López-Vázquez A, Rodríguez-Ezpeleta N, Mendibil I, Sánchez A, Torre-Alonso JC, Bettencourt BF, Mulero J,Collantes E, López-Larrea C. Fine mapping of a major histocompatibility complex in ankylosing spondylitis: association of the HLA-DPA1 and HLA-DPB1 regions. Arthritis Rheum. 2011 Nov;63(11):3305-12.
6.-Association of the intergenic single-nucleotide polymorphism rs10865331 (2p15) with ankylosing spondylitis in a Spanish population. Sánchez A, Szczypiorska M, Juanola X, Bartolomé N, Gratacós J, Zarco P, Collantes E, Artieda M, Martínez A, Tejedor D, Mulero J. J Rheumatol. 2010 Nov;37(11):2345-7.
"The artificial pancreas, a little closer"
- Viernes 22 de junio de 2012 - 17.00 horas
Hotel Barceló Málaga Calle Héroes de Sostoa, 2
Tadej Battelino, M.D., Ph.D.
Professor of Pediatrics Head, Dept. of Endocrinology, Diabetes & Metabolism UMC-University Children's Hospital Ljubljana Slovenia
"Endolysosomal pathways in melanoma progression and drug response"
- Jueves 15 de diciembre de 2011 - 12.00 horas
Salón de Actos del Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO)
Parque Tecnológico de Ciencias de la Salud
Avda. de la Ilustración, 114. Granada
María S. Soengas, PhD
Director, Molecular Pathology Programme Head, Melanoma Laboratory Spanish National Cancer Research Centre (CNIO)
Damiá Tormo, PhD, MBM
Director General. Bioncotech Therapeutics
* Selected references:
1.-Denoyelle C., Abou-Rjaily G., Veerzokove V., Verhaegen M., Johnson, T., Fullen D., Pointer J., Gruber S., Su L., Nikiforov, M., Kaufman R., Bastian B.E., and Soengas M.S. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway (2006). Nat. Cell Biology 8(10):1053-63.
2.-Tormo D, CheciÅ„ska A, Alonso-Curbelo D, Pérez-Guijarro E, Cañón E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megías D, Mulero F, Piris MA, Dash R, Barral PM, Rodríguez-Peralto JL, Ortiz-Romero P, Tüting T, Fisher PB and Soengas MS. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells (2009). Cancer Cell 16(2):103-14 (Cover; see Commentaries by Ronai. Z, Cancer Cell. 2009 Aug 4;16(2):83-4; Goldszmid R.S., Hasan, U.A and Trinchieri G. Pigment Cell and Melanoma Research 2009, 22(6) 705-706. Vojo Deretic.2009 Faculty of 1000).
3.-Verhaegen M., Checinska A., Riblett MB, Wang S and Soengas MS. E2F1 dependent oncogenic addiction of melanoma cells to MDM2 (2011). Oncogene (epub ahead of print Jul 11. doi: 10.1038/onc.2011).
4.-Checinska A and Soengas MS. The gluttonous side of malignant melanoma: basic and clinical implications of autophagy (2011). Pigment Cell and Melanoma Research, 24(6):1116-32.
2.-Tormo D, CheciÅ„ska A, Alonso-Curbelo D, Pérez-Guijarro E, Cañón E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megías D, Mulero F, Piris MA, Dash R, Barral PM, Rodríguez-Peralto JL, Ortiz-Romero P, Tüting T, Fisher PB and Soengas MS. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells (2009). Cancer Cell 16(2):103-14 (Cover; see Commentaries by Ronai. Z, Cancer Cell. 2009 Aug 4;16(2):83-4; Goldszmid R.S., Hasan, U.A and Trinchieri G. Pigment Cell and Melanoma Research 2009, 22(6) 705-706. Vojo Deretic.2009 Faculty of 1000).
3.-Verhaegen M., Checinska A., Riblett MB, Wang S and Soengas MS. E2F1 dependent oncogenic addiction of melanoma cells to MDM2 (2011). Oncogene (epub ahead of print Jul 11. doi: 10.1038/onc.2011).
4.-Checinska A and Soengas MS. The gluttonous side of malignant melanoma: basic and clinical implications of autophagy (2011). Pigment Cell and Melanoma Research, 24(6):1116-32.
"Novel retinal therapeutics: from cells to man"
- Martes 19 de julio 2011
Salón de Actos del Instituto de Biomédicina de Sevilla
Campus Hospital Universitario Virgen del Rocío
Avd. Manuel Siurot, s/n. Sevilla
Shalesh Kaushal, PhD
Department of Ophthalmology and Cell Biology
University of Massachusetts Medical School
* Selected references:
1.- Kleinberg T, Tzekov R, Stein L, Ravi N, Kaushal S. 2011. Vitreous substitutes: a comprehensive review. Survey of Ophthalmology. Accepted for publication
2.- Stein L, Roy K, Lei L, Kaushal S. 2011. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis. Expert Opin Biol Ther. Accepted for publication
3.- Clemson,C.M., Tzekov R., Krebs, M., Checchi, J.m., Bigelow, C., Kaushal. S. 2010. Therapeuti potential of valproic aci for retinitis pigmentosa. Brithish Journal of Ophthalmology. July 20, 2010 [epub ahead of print - doi: 10.1136/bjo.2009.175356]
4.- Krebs, M.P., Holden, D.C., Joshi, P., Clark III, C.L., Lee, A.H., Kaushal, S.. 2010.Molecula mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. Journal of Molecular Biology. Nov 11 2009 [epub ahead of print]
2.- Stein L, Roy K, Lei L, Kaushal S. 2011. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis. Expert Opin Biol Ther. Accepted for publication
3.- Clemson,C.M., Tzekov R., Krebs, M., Checchi, J.m., Bigelow, C., Kaushal. S. 2010. Therapeuti potential of valproic aci for retinitis pigmentosa. Brithish Journal of Ophthalmology. July 20, 2010 [epub ahead of print - doi: 10.1136/bjo.2009.175356]
4.- Krebs, M.P., Holden, D.C., Joshi, P., Clark III, C.L., Lee, A.H., Kaushal, S.. 2010.Molecula mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue. Journal of Molecular Biology. Nov 11 2009 [epub ahead of print]
"Degeneration and regeneration of myelin after spinal cord injury: debunking speculation and seeing reality"
- Jueves 2 de junio 2011
Salón de Actos del Instituto de Investigación Biomédica de Sevilla (IBIS)
Campus Hospital Universitario Virgen del Rocío
Avd. Manuel Siurot, s/n. Sevilla
Philip J. Horner, PhD
Associate Professor of Neurosurgery
University of Washington
Institute for Stem Cell and Regenerative Medicine
Seattle, WA
* Selected references:
1.- Jurate Lasiene, Aya Matsui, Yuhito Sawa, Fernando Wong, Philip J. Horner. 2009. Age-related myelin dynamics revealed by increased oligodendrogenesis and short internodes. Aging Cell, 2009. Apr;8(2):201-13. PMID: 19338498
2.- Lasiene, J., L. Shupe, S. Perlmutter, P.J. Horner. 2008. No evidence for chronic demyelination in spared axons following spinal cord injury in a mouse. Journal of Neuroscience, 9;28(15):3887-96. PMID: 18400887
3.- White, B.D., R.J. Nathe, D.O. Maris, N.K. Nguyen, J.M. Goodson, R.T. Moon, and P.J. Horner. 2009. bcatenin signaling increases in proliferating NG2+ progenitors and astrocytes during posttraumatic gliogenesis in the adult brain. Stem Cells. (2):297-307. PMID: 19960516
4.- Bosco, A., D.M.Inman, M.R.Steele, G.Wu, N.Marsh-Armstrong, D.J. Calkins, P.J. Horner, M.L.Vetter. 2008. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. IOVS, 49(4):1437-46. PMID: 18385061
5.- Drew L. Sellers, Don O. Maris, and P.J. Horner. 2009. Post-injury niches direct temporal shifts in progenitor fate-choice to direct niche succession and repair after spinal cord injury. Journal of Neuroscience, 29(20):6722-33. PMID: 19458241
6.- Baltan, S, D.M. Inman, C. Danilov, R.S. Morrisona D.J. Calkins, P.J. Horner. 2010. Metabolic vulnerability disposes axons to dysfunction in a model of glaucomatous degeneration. Journal of Neuroscience. 30(16):5644-52, PMID: 20410117, /with cover/
7.- Crish, S.D., R.M. Sappington, D.M. Inman, P.J. Horner and D.J. Calkins. 2010. Distal Axonopathy with Structural Persistence in Glaucomatous Neurodegeneration. Proceedings of the National Academy of Sciences, 107(11):5196-201, PMID: 20194762
2.- Lasiene, J., L. Shupe, S. Perlmutter, P.J. Horner. 2008. No evidence for chronic demyelination in spared axons following spinal cord injury in a mouse. Journal of Neuroscience, 9;28(15):3887-96. PMID: 18400887
3.- White, B.D., R.J. Nathe, D.O. Maris, N.K. Nguyen, J.M. Goodson, R.T. Moon, and P.J. Horner. 2009. bcatenin signaling increases in proliferating NG2+ progenitors and astrocytes during posttraumatic gliogenesis in the adult brain. Stem Cells. (2):297-307. PMID: 19960516
4.- Bosco, A., D.M.Inman, M.R.Steele, G.Wu, N.Marsh-Armstrong, D.J. Calkins, P.J. Horner, M.L.Vetter. 2008. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. IOVS, 49(4):1437-46. PMID: 18385061
5.- Drew L. Sellers, Don O. Maris, and P.J. Horner. 2009. Post-injury niches direct temporal shifts in progenitor fate-choice to direct niche succession and repair after spinal cord injury. Journal of Neuroscience, 29(20):6722-33. PMID: 19458241
6.- Baltan, S, D.M. Inman, C. Danilov, R.S. Morrisona D.J. Calkins, P.J. Horner. 2010. Metabolic vulnerability disposes axons to dysfunction in a model of glaucomatous degeneration. Journal of Neuroscience. 30(16):5644-52, PMID: 20410117, /with cover/
7.- Crish, S.D., R.M. Sappington, D.M. Inman, P.J. Horner and D.J. Calkins. 2010. Distal Axonopathy with Structural Persistence in Glaucomatous Neurodegeneration. Proceedings of the National Academy of Sciences, 107(11):5196-201, PMID: 20194762
"Smart biologicals to fight cancer: pursuing 'pre-omic' killing efficienciesand 'post-omics' target selectivities"
- Lunes 22 de noviembre de 2010 - 12:30 h
Aula de formación del Centro-Pfizer - Universidad de Granada - Junta de Andalucía de Genómica e Investigación Oncológica (GENYO)
Avd. de Ilustración, 114. Parque Tecnológico de Ciencias de la Salud. Granada
Dr. Guillero de la Cueva Méndez
Unidad Celular del Cáncer.
Hutchinson-Medical Research Council.
Cambrigde
* Selected references:
1.-Pimentel et al., 2005. EMBO J., 24: 3459-3469
2.-Slanchev et al., 2005. Proc NatlAcadSci USA.,102: 4074-4079
3.-De la Cueva-Mendez et al., 2003. EMBO J., 22: 246-251
2.-Slanchev et al., 2005. Proc NatlAcadSci USA.,102: 4074-4079
3.-De la Cueva-Mendez et al., 2003. EMBO J., 22: 246-251
"Engineering Biofunctional Nanoparticles"
- Lunes 5 de julio de 2010 - 12:00 h
Salón de Actos - Edificio de Bioinnovación.Parque Tecnológico de Andalucía (PTA)
c/ Severo Ochoa, 34 · 29590 Campanillas, Málaga
Dr. Jesús M. de la Fuente
Grupo de Nanopartículas y Superficies Biofuncionales (bioNANOsurf).
Instituto de Nanociencias de Aragón (INA)
Universidad de Zaragoza
* Selected references:
1.-Niemeyer C.M. Angew. Chem. Int. En. Ed. 40, 4128 (2001)
2.-(a) Daniel M.C.; Astruc D. Chem. Rev. 104, 293 (2004)
(b) Berry C.C. Curtis A.S.G. J. Phys D: Appl. Phys. 36, R198 (2003)
3.-Prime K. L.; Whitesides G. M. Science 252, 1164 (1991)
2.-(a) Daniel M.C.; Astruc D. Chem. Rev. 104, 293 (2004)
(b) Berry C.C. Curtis A.S.G. J. Phys D: Appl. Phys. 36, R198 (2003)
3.-Prime K. L.; Whitesides G. M. Science 252, 1164 (1991)
"Producción de alfa-defensinas 1-3 por las células dendríticas mieloides: su papel como factor protector frente a la progresión de la infección por VIH-1"
- Jueves 27 de mayo de 2010 - 16:30 h
Salón de Actos - Hospital Universitario Ntra. Sra. de Valme.
Ctra. de Cádiz, km. 548,9 - 41014 Sevilla
Dra. Teresa Gallart
Servicio de Inmunología
Grupo de Investigación sobre el SIDA-IDIBAPS
Hospital Clínic de Barcelona
* Selected references:
1.-PLoS One. 2010 Feb 25;5(2):e9436.
2.-Clinical Immunology 2009;131:374-84.
3.-Journal of Leukocyte Biology 2007;82:1143-6.
4.-Proceedings of the National Academy of Sciences of the U. S. A. 2005;102:9583-8.
5.-Journal of Infectious Diseases 2005;191:1680-5
2.-Clinical Immunology 2009;131:374-84.
3.-Journal of Leukocyte Biology 2007;82:1143-6.
4.-Proceedings of the National Academy of Sciences of the U. S. A. 2005;102:9583-8.
5.-Journal of Infectious Diseases 2005;191:1680-5
"Genetics of colorectal cancer"
- Miércoles 9 de Diciembre de 2009 - 12:00 h
Edificio BIC Granada. Parque tecnológico de Ciencias de la Salud
Av. de la Innovación 1 - 18100 Armilla - Granada
Dr. Albert Tenesa
School of Molecular and Clinical Medicine
THE UNIVERSITY OF EDIMBURGH. SCOTLAND
"How pluripotent are my reprogrammed cells? Answers from gene expression microarrays"
- Jueves 26 de Noviembre de 2009 - 12:00 h
Edificio BIC Granada. Parque tecnológico de Ciencias de la Salud
Av. de la Innovación 1 - 18100 Armilla - Granada
Marcos J. Arauzo-Bravo, PhD
Department Cell and Developmental Biology Group of Computational Biology and Bioinformatics
MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE. Münster, GERMANY
"The role and future of human Biobanks in post-genome research"
- Martes 21 de Julio de 2009 - 12:00 h
Edificio BIC Granada. Parque tecnológico de Ciencias de la Salud
Av. de la Innovación 1 - 18100 Armilla - Granada
.jpg)
Prof. Bill Ollier
Professor of Immunogenetics / Director of the Centre for Integrated Genomic Medical Research (CIGMR).
MANCHESTER UNIVERSITY
"Biological applications of colloidal nanoparticles-how nanotechnology can contribute to diagnosis and treatment"
- Viernes 06 de Marzo de 2009 - 12:00 h
Salón de Actos Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER):Avda. Americo Vespucio s/n. Parque Científico y Tecnológico Cartuja 93, Sevilla
- Viernes 13 de Marzo de 2009 - 10:30 h
Salón de Grados Facultad de Ciencias. Campus de Teatinos.Universidad de Málaga. Avda. Cervantes, 2. 29071 Málaga
.jpg){kind=small}
.jpg){kind=small}
.jpg){kind=small}
Wolfgang Parak
Biophotonics Group Philipps University of Marburg, Germany
* Selected references:
1.-Chem. Soc. Rev. 2008; 37:1896-1908
2.-Small. 2008; 4(10):1763-8
3.-Journal of Materials Chemestry. 2007; 17:1343-6
4.-Small. 2007; 3:944-955
5.-NanoLetters. 2007; 7:2422-7
6.-NanoLetters. 2007; 7:2613-7
7.-Small. 2006; 394-400
8.-Angewandte Chemie International Edition. 2006; 45:4612-7
9.-NanoLetters. 2004; 7:703-7
2.-Small. 2008; 4(10):1763-8
3.-Journal of Materials Chemestry. 2007; 17:1343-6
4.-Small. 2007; 3:944-955
5.-NanoLetters. 2007; 7:2422-7
6.-NanoLetters. 2007; 7:2613-7
7.-Small. 2006; 394-400
8.-Angewandte Chemie International Edition. 2006; 45:4612-7
9.-NanoLetters. 2004; 7:703-7
"Mechanisms of disease: Genomics of lupus erythematosus"
- Jueves 13 de Noviembre de 2008 - 12:30 h
Salón de Actos Centro de Investigación Biomédica, Parque Tecnológico de Ciencias de la Salud. Avda. del Conocimiento s/n 18100 Armilla. Granada:
Dra. Marta E. Alarcón-Riquelme
Royal Swedish Academy of Sciences - Department of Genetics and Pathology. University of Uppsala,Sweden
* Selected references:
1.-Nat Genet. 2008; 40:211-6
2.-Nat Genet. 2008; 40:204-10
3.-Nat Genet. 2006; 38:866-7
4.-Nat Genet. 2006; 38:550-5
5.-Nat Genet. 2003; 35:299-300
6.-Nat Genet- 2002; 32:666-9
2.-Nat Genet. 2008; 40:204-10
3.-Nat Genet. 2006; 38:866-7
4.-Nat Genet. 2006; 38:550-5
5.-Nat Genet. 2003; 35:299-300
6.-Nat Genet- 2002; 32:666-9
"From Nanotechnology to Medicine: A physical approach to protein aggregation"
- Lunes 9 de Junio de 2008 - 12:00 h
Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER):
"Protein aggregation: a nanotech study approach of a main medical problem"
- Martes 10 de Junio- 13:00 h
Universidad de Málaga. Facultad Ciencias, Campus Teatinos (Salón de Actos):
Dr. Tuomas Knowles
Cavendish Laboratory, Department of Physics and Center for Nanoscience University of Cambridge Cambridge, UK
* Selected references:
1.-Science. 2007; 318:1900-3
2.-J Mol Biol. 2007; 372:470-84
3.-Proc Natl Acad Sci U S A. 2007; 104:10016-21
4.-Proc Natl Acad Sci U S A. 2006; 103:15806-11
5.-Phys Rev Lett. 2006; 96:238301
6.-J Mol Biol. 2006; 360:497-509
2.-J Mol Biol. 2007; 372:470-84
3.-Proc Natl Acad Sci U S A. 2007; 104:10016-21
4.-Proc Natl Acad Sci U S A. 2006; 103:15806-11
5.-Phys Rev Lett. 2006; 96:238301
6.-J Mol Biol. 2006; 360:497-509
"Systems biology in multiple sclerosis: accessing global information about the state of the body"
- Jueves 17 de Abril de 2008 - 13:30 h
Fundación IMABIS. H. Materno Infantil Málaga (Salón de Actos):
"Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor"
- Lunes 21 de Abril de 2008 - 12:00 h.
Centro Andaluz de Biología del Desarrollo (CABD):
"Understanding multiple sclerosis pathological autoimmunity by antigen microarray informatics: New targets for therapeutic inmmunomodulation"
- Martes 22 de Abril de 2008 - 12:00 h.
Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER)
Dr. Francisco Javier Quintana
Center for Neurologic Diseases, Harvard Medical School, Boston, USA
* Selected references:
1.-Nature. 2008 Mar 23; [Epub ahead of print]
2.-J. Clin Invest. 2008 Mar 13; [Epub ahead of print]
3.-J. Clin Invest. 2007 Mar;117(3):712-8
4.-J. Clin Invest. 2004 Nov;114(9):1227-32
5.-Proc. Natl. Acad. Sci. USA. 2004, 101, 14615-21
2.-J. Clin Invest. 2008 Mar 13; [Epub ahead of print]
3.-J. Clin Invest. 2007 Mar;117(3):712-8
4.-J. Clin Invest. 2004 Nov;114(9):1227-32
5.-Proc. Natl. Acad. Sci. USA. 2004, 101, 14615-21
Fundación Progreso y Salud - Avda. Américo Vespucio 5, Bloque 2, 2ª Planta - Parque Científico y Tecnológico Cartuja
41092 - Sevilla Tel.: 955 04 04 50. Fax: 955 04 04 57 - fundacion.progreso.salud@juntadeandalucia.es - Nota legal - Webmaster
41092 - Sevilla Tel.: 955 04 04 50. Fax: 955 04 04 57 - fundacion.progreso.salud@juntadeandalucia.es - Nota legal - Webmaster
